Remarkably, this combination appeared effective against the notorious TP53 mutant AML as well, with 71% of patients achieving an objective response, 48% achieving a CR, and 19% achieving a CRi in TP53 mutant AML patients. Here, TP53 is linked to acute myeloid leukemia.